Which has stronger valuation and earnings, LFMD or TALK?

LifeMD has higher earnings, but lower revenue than Talkspace. LifeMD is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.18 $14.35M $0.05 95.00 Talkspace $228.87M 3.81 $7.79M $0.01 521.00

Is LFMD or TALK more profitable?

LifeMD has a net margin of 2.37% compared to Talkspace's net margin of 0.49%. Talkspace's return on equity of 1.03% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Talkspace 0.49% 1.03% 0.88%

Is CSTL or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Castle Biosciences -3.78% -2.77% -2.30% LifeMD 2.37% -150.88% -22.59%

Is LFMD or FLGT more profitable?

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Fulgent Genetics -23.04% -3.24% -2.97%

Do analysts recommend LFMD or MCTA?

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 92.48%. Given LifeMD's stronger consensus rating and higher probable upside, equities research analysts clearly believe LifeMD is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, LFMD or MCTA?

LifeMD has higher revenue and earnings than Charming Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.18 $14.35M $0.05 95.00 Charming Medical $5.42M 91.68 N/A N/A N/A

LifeMD (LFMD) Competitors

$4.75 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$4.71 -0.04 (-0.82%)

As of 06/18/2026 07:23 PM Eastern

Compare

LFMD vs. TALK, CSTL, FLGT, TOI, and MCTA

Should you buy LifeMD stock or one of its competitors? MarketBeat compares LifeMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LifeMD include Talkspace (TALK), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Oncology Institute (TOI), and Charming Medical (MCTA). These companies are all part of the "healthcare" industry.

How does LifeMD compare to Talkspace?

LifeMD (NASDAQ:LFMD) and Talkspace (NASDAQ:TALK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

LifeMD has higher earnings, but lower revenue than Talkspace. LifeMD is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.18	$14.35M	$0.05	95.00
Talkspace	$228.87M	3.81	$7.79M	$0.01	521.00

LifeMD currently has a consensus price target of $9.14, indicating a potential upside of 92.48%. Talkspace has a consensus price target of $5.56, indicating a potential upside of 6.77%. Given LifeMD's stronger consensus rating and higher possible upside, research analysts clearly believe LifeMD is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Talkspace had 2 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for Talkspace and 0 mentions for LifeMD. Talkspace's average media sentiment score of 0.06 beat LifeMD's score of 0.00 indicating that Talkspace is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Neutral
Talkspace	Neutral

LifeMD has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Talkspace has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

LifeMD has a net margin of 2.37% compared to Talkspace's net margin of 0.49%. Talkspace's return on equity of 1.03% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Talkspace	0.49%	1.03%	0.88%

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 57.4% of Talkspace shares are owned by institutional investors. 17.2% of LifeMD shares are owned by insiders. Comparatively, 23.5% of Talkspace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Talkspace beats LifeMD on 9 of the 16 factors compared between the two stocks.

How does LifeMD compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

LifeMD has lower revenue, but higher earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	1.86	-$24.16M	-$0.44	N/A
LifeMD	$194.05M	1.18	$14.35M	$0.05	95.00

Castle Biosciences has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Castle Biosciences currently has a consensus target price of $42.83, suggesting a potential upside of 102.81%. LifeMD has a consensus target price of $9.14, suggesting a potential upside of 92.48%. Given Castle Biosciences' higher possible upside, equities analysts clearly believe Castle Biosciences is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-3.78%	-2.77%	-2.30%
LifeMD	2.37%	-150.88%	-22.59%

In the previous week, Castle Biosciences had 7 more articles in the media than LifeMD. MarketBeat recorded 7 mentions for Castle Biosciences and 0 mentions for LifeMD. LifeMD's average media sentiment score of 0.00 beat Castle Biosciences' score of -0.27 indicating that LifeMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Castle Biosciences	Neutral
LifeMD	Neutral

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

LifeMD beats Castle Biosciences on 9 of the 16 factors compared between the two stocks.

How does LifeMD compare to Fulgent Genetics?

LifeMD (NASDAQ:LFMD) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

LifeMD has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.18	$14.35M	$0.05	95.00
Fulgent Genetics	$320.35M	1.59	-$60.51M	-$2.39	N/A

LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 92.48%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 50.33%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts clearly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

In the previous week, LifeMD's average media sentiment score of 0.00 equaled Fulgent Genetics'average media sentiment score.

Company	Overall Sentiment
LifeMD	Neutral
Fulgent Genetics	Neutral

35.5% of LifeMD shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LifeMD has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

LifeMD beats Fulgent Genetics on 8 of the 14 factors compared between the two stocks.

How does LifeMD compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 4.4% of Oncology Institute shares are held by insiders. Comparatively, 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncology Institute currently has a consensus target price of $7.75, indicating a potential upside of 47.34%. LifeMD has a consensus target price of $9.14, indicating a potential upside of 92.48%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Oncology Institute has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, LifeMD has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

In the previous week, Oncology Institute had 2 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for Oncology Institute and 0 mentions for LifeMD. Oncology Institute's average media sentiment score of 1.00 beat LifeMD's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Positive
LifeMD	Neutral

LifeMD has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	1.03	-$60.61M	-$0.37	N/A
LifeMD	$194.05M	1.18	$14.35M	$0.05	95.00

LifeMD has a net margin of 2.37% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
LifeMD	2.37%	-150.88%	-22.59%

Summary

LifeMD beats Oncology Institute on 11 of the 16 factors compared between the two stocks.

How does LifeMD compare to Charming Medical?

LifeMD (NASDAQ:LFMD) and Charming Medical (NASDAQ:MCTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LifeMD has a net margin of 2.37% compared to Charming Medical's net margin of 0.00%. Charming Medical's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Charming Medical	N/A	N/A	N/A

LifeMD has higher revenue and earnings than Charming Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.18	$14.35M	$0.05	95.00
Charming Medical	$5.42M	91.68	N/A	N/A	N/A

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 92.48%. Given LifeMD's stronger consensus rating and higher probable upside, equities research analysts clearly believe LifeMD is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, LifeMD's average media sentiment score of 0.00 equaled Charming Medical'saverage media sentiment score.

Company	Overall Sentiment
LifeMD	Neutral
Charming Medical	Neutral

Summary

LifeMD beats Charming Medical on 7 of the 10 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$229.71M	$8.77B	$6.39B	$12.59B
Dividend Yield	N/A	1.73%	2.68%	5.68%
P/E Ratio	95.02	24.73	24.54	24.44
Price / Sales	1.18	16.61	574.69	128.57
Price / Cash	N/A	93.62	44.20	55.21
Price / Book	9.90	5.64	10.83	6.58
Net Income	$14.35M	$179.69M	$3.57B	$337.17M
7 Day Performance	1.06%	1.74%	0.71%	0.61%
1 Month Performance	10.47%	9.17%	3.97%	5.02%
1 Year Performance	-68.46%	5.21%	28.50%	35.50%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	2.5421 of 5 stars	$4.75 flat	$9.14 +92.5%	-68.5%	$229.71M	$194.05M	95.02	230
TALK Talkspace	2.1208 of 5 stars	$5.20 -0.2%	$5.56 +7.0%	+88.1%	$872.74M	$228.87M	520.52	500	Insider Trade
CSTL Castle Biosciences	3.0193 of 5 stars	$20.66 -0.2%	$42.83 +107.3%	+11.7%	$627.83M	$344.23M	N/A	540	News Coverage Insider Trade Gap Down
FLGT Fulgent Genetics	2.1301 of 5 stars	$18.35 -1.8%	$27.00 +47.1%	-11.5%	$530.52M	$322.67M	N/A	1,315
TOI Oncology Institute	3.9899 of 5 stars	$5.18 -2.4%	$7.25 +40.0%	+121.0%	$524.84M	$502.73M	N/A	660	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. TALK, CSTL, FLGT, TOI, and MCTA

How does LifeMD compare to Talkspace?

Summary

How does LifeMD compare to Castle Biosciences?

Summary

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Oncology Institute?

Summary

How does LifeMD compare to Charming Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. TALK, CSTL, FLGT, TOI, and MCTA

How does LifeMD compare to Talkspace?

Which has stronger valuation and earnings, LFMD or TALK?

Do analysts rate LFMD or TALK?

Does the media prefer LFMD or TALK?

Which has more risk & volatility, LFMD or TALK?

Is LFMD or TALK more profitable?

Do institutionals & insiders believe in LFMD or TALK?

Summary

How does LifeMD compare to Castle Biosciences?

Which has stronger valuation & earnings, CSTL or LFMD?

Which has more volatility and risk, CSTL or LFMD?

Do analysts prefer CSTL or LFMD?

Is CSTL or LFMD more profitable?

Does the media favor CSTL or LFMD?

Do insiders and institutionals hold more shares of CSTL or LFMD?

Summary

How does LifeMD compare to Fulgent Genetics?

Which has preferable earnings & valuation, LFMD or FLGT?

Do analysts prefer LFMD or FLGT?

Is LFMD or FLGT more profitable?

Does the media refer more to LFMD or FLGT?

Do institutionals and insiders hold more shares of LFMD or FLGT?

Which has more risk and volatility, LFMD or FLGT?

Summary

How does LifeMD compare to Oncology Institute?

Do institutionals & insiders have more ownership in TOI or LFMD?

Do analysts prefer TOI or LFMD?

Which has more volatility & risk, TOI or LFMD?

Does the media favor TOI or LFMD?

Which has preferable valuation and earnings, TOI or LFMD?

Is TOI or LFMD more profitable?

Summary

How does LifeMD compare to Charming Medical?

Do insiders and institutionals hold more shares of LFMD or MCTA?

Is LFMD or MCTA more profitable?

Which has higher earnings and valuation, LFMD or MCTA?

Do analysts recommend LFMD or MCTA?

Does the media favor LFMD or MCTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools